Intellia names Jing L. Marantz chief medical officer
NTLA•Intellia Therapeutics named Jing L. Marantz executive vice president and chief medical officer, effective Oct. 26, 2026. She will lead translational, development, regulatory and medical affairs functions as the company prepares for a first in vivo gene-editing commercialization push.
1. New medical chief
Marantz will lead Intellia’s translational, development, regulatory and medical affairs functions. She previously served as chief medical officer at Scholar Rock, where she oversaw development work that supported U.S. approval of ISEMBYLD, and held senior roles at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD and Millennium Pharmaceuticals.
